Definitive Contract W58P0522C0002
Award Date
11/15/21
Potential Completion Date
9/30/23
Potential Value
$2.9B
Funding Federal Agency
Joint PEO Chemical and Biological Defense
Contracting Federal Agency
ACC Aberdeen Proving Ground
Awardee
Glaxosmithkline, LLC
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Research Triangle Park, NC 27709, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $50,556,695.00 definitive contract awarded by the Centers for Disease Control and Prevention (CDC) to Glaxosmithkline, LLC, a pharmaceutical company that provides vaccines, antiviral medications, and other pharmaceutical products to U.S. government agencies. The contract, titled "2016 VFA - GSK", is for a firm fixed price and has an ultimate completion date of June 30, 2017. It is not a set-aside contract. Glaxosmithkline has provided a range of pharmaceutical goods and...
This is a $499,100 firm fixed price delivery order awarded by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response to Glaxosmithkline, LLC. The order is for pharmaceutical goods and services under the Pandemic Influenza Preparedness and Response 2016-2021 multiple award contract. Glaxosmithkline, a foreign-owned for-profit pharmaceutical company, provides a range of products to U.S. government agencies including influenza and hepatitis...
This federal contract award, SPE2DP16D0009|0172, was issued by the Medical Supply Chain division of the U.S. Department of Defense (DoD) to Glaxosmithkline, LLC, a pharmaceutical company, to provide zanamivir, an antiviral medication, on a firm fixed price delivery order basis. The contract has a ceiling value of $92,165.22 and a completion date of December 6, 2017. Glaxosmithkline has provided a range of pharmaceutical products and services to various federal agencies through contracts and...
This contract was awarded by the Department of Health and Human Services Office of the Assistant Secretary for Administration to the prime contractor Glaxosmithkline, LLC, a foreign-owned for-profit pharmaceutical company, to provide vaccines for the government's stock. The $172,923.02 firm fixed price delivery order was issued under Glaxosmithkline's Federal Supply Schedule 61-IB contract for pharmaceuticals and drugs. The award does not have a set-aside designation. Glaxosmithkline is a...
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Glaxosmithkline, LLC, a foreign-owned pharmaceutical company, for the supply of the antiviral medication zanamivir. The firm fixed price contract has a potential value of $39,375.00 and a completion date of March 18, 2024. The contract is not associated with a set-aside designation. Glaxosmithkline has been awarded multiple federal contracts and indefinite delivery vehicles to provide vaccines,...
This is a federal contract award from the U.S. Department of Health and Human Services to Glaxosmithkline, LLC, a pharmaceutical company, for the supply of vaccines. The contract has a ceiling value of $220,298.59 and is a firm fixed price delivery order placed against Glaxosmithkline's General Services Administration (GSA) Federal Supply Schedule (FSS) contract for Pharmaceuticals and Drugs. The contract has no set-aside designation. The contract supports the government's vaccine stockpiling...
The U.S. government agency Medical Supply Chain awarded a firm fixed price delivery order contract worth $229,284.00 to Glaxosmithkline, LLC, a pharmaceutical company, for the provision of zanamivir, an antiviral medication, with a period of performance ending on December 14, 2016. This contract was not set aside for any specific business type. Glaxosmithkline has previously been awarded other federal contracts and grants for the supply of various pharmaceutical products and services,...
This is a definitive contract awarded by the Joint PEO Chemical and Biological Defense, a component of the Department of the Army Acquisition Support Center, to Eli Lilly and Company, a for-profit manufacturer of goods. The $2,105,000,000.00 firm fixed price contract is for the delivery of LYCOV1404 BEBTELOVIMAB, a monoclonal antibody treatment, to support the government's Coronavirus COVID-19 response efforts. The contract has an ultimate completion date of September 30, 2023 and does not...
This is a delivery order contract (SPE2DP19F0724) awarded by the U.S. Department of Defense (DoD) Medical Supply Chain to Glaxosmithkline, LLC for the provision of influenza virus vaccine. The $3,582 firm fixed price contract has a completion date of November 30, 2018 and does not utilize a set-aside designation. Glaxosmithkline, a foreign-owned for-profit pharmaceutical company, has provided a range of vaccines and antiviral medications to federal agencies through multiple indefinite delivery...
This federal contract award, SPE2DP16D0009|0136, was issued by the Defense Logistics Agency (DLA) to Glaxosmithkline, LLC, a pharmaceutical company, for the delivery of zanamivir, an antiviral medication, with a ceiling value of $896,292.00. The contract is a firm fixed-price delivery order that does not have a set-aside designation. Glaxosmithkline has received multiple federal contract awards, including indefinite delivery vehicles (IDVs) with the Department of Veterans Affairs, Centers for...